Strategic Strayer Education

Shares of Strategic Education climbed to a 52-week high of 87.60 USD, posting a year-to-date performance of +16.47%. In Q2 2026 the company reported revenue of 337.47 million USD, beating analysts’ estimate of 327.55 million USD, while adjusted earnings per share of 1.76 USD slightly missed the 1.80 USD expectation. With a P/E ratio of 15.28 and aggressive buybacks, InvestingPro currently views the stock as undervalued. Revenue growth was driven by education technology and U.S. higher education, underpinning investor confidence in further growth. » More on de.investing.com

Strategic Education reported adjusted earnings per share of $1.41 for Q1, meeting the consensus estimate, while revenue of $305.9 million missed expectations of $313.8 million. The stock fell about 13% and closed near its 52-week low, pressured by declining enrollment (down 1.1% to 106,735). Operationally, the company achieved margin improvements and an increase in adjusted operating income, driven by strong growth in the education-technology services segment; the U.S. higher-education segment, however, showed declines in revenue and income. Strategic Education highlights share buybacks and an unchanged quarterly dividend, and expects revenue growth to improve later in the year thanks to education technology and employer partnerships. » More on de.investing.com

Strategic Education reported Q4 2025 revenue of $323.2 million and adjusted diluted EPS of $1.74, with results beating analyst expectations by 16%. Adjusted operating margin rose 390 basis points in the quarter to 16.9% and to 15.5% for the year, driven by cost discipline and AI-driven productivity improvements. The education-technology segment grew strongly (+41.4% for 2025) while total student enrollment in Q4 fell 3.6% to 104,820. The company reports a debt-free balance sheet, free cash flow of $153.9 million and a dividend payment of $2.40 per share, and remains focused on margin-oriented growth. » More on de.investing.com

Strategic Education reported Q4 2025 EPS of $1.66, beating the $1.43 estimate by 16.08%. Revenue was $323.2 million, slightly above expectations; operating margin rose 390 basis points to 16.9%. The company is debt-free, generated $154 million in free cash flow (including $58 million in dividends) and cites AI-driven productivity gains as a driver of cost reductions and margin improvements. Management reaffirmed plans to expand the Education Technology Services segment and expects student growth in Australia/New Zealand to return by the end of 2026; the stock rose 3.2% in after-hours trading. » More on de.investing.com

Silo Pharma announced that the Australian Patent Office granted Columbia University a patent for the intranasal PTSD therapy SPC-15, which Silo holds an exclusive license to. The company also reported positive safety data from a large-animal study for SPC-15, expects further preclinical data, and shows a high gross margin despite overall weak financial metrics. Additionally, Silo was notified by NASDAQ of non-compliance with the minimum bid price requirement, which currently does not affect trading. » More on de.investing.com